Gm-Csf
Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease
Explore 2 assets in Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Medical College of Wisconsin
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05544968CT.gov Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gm-Csf (this asset) | Medical College of Wisconsin | P1 | CC · 43 |
| Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells | Medical College of Wisconsin | P1 | CC |
Other indications for Gm-Csf
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P4 | BBB · 74 |
| Melanoma | — | P4 | BBB · 74 |
| Uveal Melanoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gm-Csf in Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gm-csf-primary-cutaneous-cd30-t-cell-lymphoproliferative-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →